Our Organization AgeX Therapeutics, Inc.
Our Organization AgeX Therapeutics, Inc.
Lavender Swirl Background
Partner

AgeX Therapeutics, Inc.

We are using proprietary technologies to develop medicines and therapies that can repair tissues in the aged human body.



AgeX Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics targeting human aging. AgeX is building upon the foundation of their proprietary technologies such as PureStem® and induced Tissue Regeneration (iTR™) to develop innovative medicines designed to address some of the largest unsolved problems in aging.

Through PureStem®, AgeX has the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is AgeX’s revolutionary longevity platform aiming to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.

AgeX is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.

AgeX was founded in 2017 and joined Juvenescence in 2018.

In the News

AgeX Therapeutics

Juvenescence Partner AgeX Therapeutics Sublicenses Stem Cell Line for Development of Covid-19 Therapy

AgeX Therapeutics announced that ImStem has obtained a non-exclusive, royalty-bearing sublicense from AgeX for development of ImStem’s investigational product candidate IMS001 for development in COVID-19 and ARDS from other causes. Screen reader support enabled.

October 28, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics and Sernova collaborate to engineer Universal Locally Immune Protected Cell Therapies

AgeX, a Juvenescence partner, and Sernova collaborate to utilize AgeX’s UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for the treatment of type I diabetes and hemophilia A.

May 29, 2020

Read More
AgeX Therapeutics

AgeX Therapeutics Announces Agreement with Pluristyx

AgeX Therapeutics announces a manufacturing, marketing and distribution agreement with Pluristyx, an advanced therapy tools and services company, to expand access to clinical-grade human pluripotent stem cells for therapeutic applications.

June 15, 2020

Read More

Contact Us

We are here to help answer any questions you might have.